Explore the latest news about Venture Partners at CU Boulder and keep up to date on the impact CU's startups and technologies are making.

Methane monitoring device

LongPath Technologies raises $22M Series A to meet accelerating demand for its patented methane monitoring network

Dec. 5, 2022

CU Boulder startup LongPath Technologies, a leading provider of patented continuous emissions detection and quantification technology, has raised $22 million in Series A funding. The round included Buff Gold Ventures, a firm focused on deep tech investments coming out of the University of Colorado.

Tyler Hernandez and Michael Strand

Cofounders of CU Boulder startup named Forbes 30 Under 30

Dec. 1, 2022

Forbes—Using a technology called reversible metal electrodeposition, Tynt Technologies makes windows with the ability to adjust their tint to optimize visual and thermal comfort and reduce building energy consumption from light and HVAC use. Cofounders Tyler Hernandez and Michael Strand were named on the Forbes 30 Under 30 list.

Scott Faris

CU Boulder ColdQuanta adopts a new umbrella brand: Infleqtion

Nov. 30, 2022

Inside Quantum Technology—As the quantum industry continues to mature, many companies are maturing and changing alongside it. One of these is ColdQuanta. In an announcement earlier today, the company has created its new umbrella brand, Infleqtion.

Scientist in a laboratory

CU Boulder commercialization drives $8 billion impact nationwide

Nov. 28, 2022

Commercialization activities led by Venture Partners at the University of Colorado Boulder had an economic impact of $8 billion nationally and $5.2 billion in the state of Colorado over the last five years, according to a new report from the Leeds School of Business.

Aerial view of CU Boulder campus

CU Boulder paves the way for start-ups using ‘Licensing with EASE®’ model

Nov. 22, 2022

From Tech Transfer Central — Since launching its Licensing with EASE® express agreement for start-up entrepreneurs in 2018, CU Boulder has seen its number of startups “increase dramatically,” according to Brynmor Rees, associate vice chancellor for research & innovation and managing director of Venture Partners.

Quantum computer

CU Boulder startup ColdQuanta's Albert named in TIME's Best Inventions of 2022

Nov. 18, 2022

With this technology, once accessible only to professional scientists but now free to all, researchers can remotely use CU Boulder startup ColdQuanta’s quantum-matter machine to design potentially transformative innovations.

Winners hold up their large prize checks

CU Boulder innovators awarded $1.25 million in commercialization funding

Nov. 9, 2022

Twelve teams of University of Colorado faculty, researchers and graduate student innovators competed for a combined $1.25 million in startup funding grants in this year’s Venture Challenge (LVC).

Johnny Hergert and Camila Uzcategui on the CU Boulder campus

Key investment is the latest milestone for CU Boulder startup Vitro3D and founders Camila Uzcategui and Johnny Hergert

Nov. 2, 2022

Vitro3D, a CU Boulder startup pioneering volumetric 3D printing for life sciences, just closed its first investment round of $1.3 million. The hard-won vote of confidence from the investment community will allow the promising new venture to pursue ambitious technical advances while continuing to build critical business capacity.

Man working on small device

ColdQuanta announces $110M Series B to continue commercializing quantum technology products across the global ecosystem

Nov. 1, 2022

ColdQuanta, a CU Boulder spinout and the global quantum ecosystem leader, announced a $110 million Series B round of funding to continue commercializing the company’s product portfolio, including quantum computing, quantum algorithms and applications, atomic clocks, sensors and components.

CU Boulder startup Arpeggio Biosciences raises $17M in Series A funding led by builders VC

Arpeggio Biosciences raises $17M in Series A funding led by Builders VC

Sept. 20, 2022

Arpeggio’s technology isolates a drug’s effect on entire transcriptomes and has identified new modulators of hard-to-drug proteins like transcription factors. Funding was led by Builders VC and will support ongoing development of Arpeggio’s drug pipeline as well as its transcription-monitoring technologies.

Pages